| Popis: |
Background: RASSF1A is a tumor suppressor gene. The methylation of RASSF1A has been reported to be associated with the nasopharyngeal tumorigenesis. However, the heterogeneity was high among different studies. This meta-analysis aimed to evaluate the value of RASSF1A methylation for diagnosing and early screening NPC. Methods: Relevant articles were identified by searching MEDLINE database. The frequency and Odds ratio (OR) were applied to estimate the effect of CDH-1 methylation based on random-/fix-effect models. A meta-analysis was performed by using MedCalc® software. The subgroup analyses were performed by test-method, ethnicity, source of NPC samples to determine likely sources of heterogeneity. Results: Total of 16 studies, included 1,548 samples: 1,095 samples from NPC samples, and 453 from non-cancerous samples, were enrolled in the meta-analysis. The overall frequency of RASSF1A methylation were 59.22% and 1.72% in case-group and control-group, respectively. By removing the poor relative studies, the heterogeneity was not observed among included studies. The association between the RASSF1A gene methylation and risk of NPC was also confirmed by calculating OR value of 37.74 (95%OR = 20.07-70.98) in fix-effect model (Q = 13.56, p = 0.48, I2 = 0.00, 95% CI = 0.00-52.19). Additionally, the significant association was also found between the methylation of RASSF1A gene and subgroups. Conclusion: This was the first meta-analysis provided scientific evidences to suggest the RASSF1A methylation was the potential diagnosis, prognosis and early screening biomarker for NPC. |
